BRAF-mutant Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

 Breaking News
  • No posts were found

BRAF-mutant Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

BRAF-mutant Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) Pipeline Insight 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the BRAF-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in BRAF-mutant Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ BRAF-mutant Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report

  • April 2024:- Pfizer– This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
  • April 2024:- Immuneering Corporation- A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations. This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.
  • DelveInsight’s BRAF-mutant Non-Small Cell Lung Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for BRAF-mutant Non-Small Cell Lung Cancer treatment.
  • The leading BRAF-mutant Non-Small Cell Lung Cancer Companies such as Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
  • Promising BRAF-mutant Non-Small Cell Lung Cancer Therapies such as IMM-6-415, binimetinib, encorafenib, Trametinib, Dabrafenib, and others.

Stay informed about the cutting-edge advancements in BRAF-mutant Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ BRAF-mutant Non-Small Cell Lung Cancer Clinical Trials Assessment

BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile

  • Encorafenib/Binimetinib: Pierre Fabre Medicament

BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The combination is currently investigated in Metastatic BRAFV600-mutant Non-Small Cell Lung Cancer in Phase II trial with completion expected in March 2025. This combination is indicated and being tested for several other indications.

  • XP-102: Xynomic Pharmaceuticals, Inc.

XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia. The drug is currently being investigated for several tumor including non-small cell lung cancer in Phase I/II which is expected to be completed by December 2024.

Learn more about BRAF-mutant Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking BRAF-mutant Non-Small Cell Lung Cancer Research and development projects @ BRAF-mutant Non-Small Cell Lung Cancer Unmet Needs

BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

BRAF-mutant Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in BRAF-mutant Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ BRAF-mutant Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • BRAF-mutant Non-Small Cell Lung Cancer Companies- Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics, Inc., and others.
  • BRAF-mutant Non-Small Cell Lung Cancer Therapies- IMM-6-415, binimetinib, encorafenib, Trametinib, Dabrafenib, and others.
  • BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • BRAF-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of BRAF-mutant Non-Small Cell Lung Cancer Pipeline on our website @ BRAF-mutant Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. BRAF-mutant Non-Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. BRAF-mutant Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase II)
  8. Encorafenib/Binimetinib: Pierre Fabre Medicament
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase I/II)
  11. XP-102: Xynomic Pharmaceuticals, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
  21. BRAF-mutant Non-Small Cell Lung Cancer Key Products
  22. BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
  23. BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
  24. BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
  25. BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
  26. BRAF-mutant Non-Small Cell Lung Cancer Key Companies
  27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories